Roche partners with Atavistik Bio for allosteric drug discovery in CVRM diseases
Atavistik Bio has entered into a collaboration with Roche to discover new small molecule therapeutics targeting cardiovascular, renal, and metabolic (CVRM) diseases. The partnership leverages Atavistik's AMPS platform, which identifies novel functional binding pockets for allosteric drug development. This alliance aims to advance innovative treatments by focusing on multiple targets within the CVRM space using a cutting-edge discovery approach. Roche is known for its leadership in pharmaceutical innovation and has previously invested heavily in cardiovascular therapies, making this partnership strategically significant. The collaboration highlights growing interest in allosteric modulation as an alternative mechanism of action compared to traditional orthosteric drug development.
Tickers: $RHHBY
Topics: CVRM diseases drug discovery pharmaceuticals small molecule therapeutics